View
1
Download
0
Category
Preview:
Citation preview
Global integrated development of new medicines;
Quality management
Márta Vajdai PharmD
Quality Manager, Internal Audit EMEA
PPD, Global Quality & Compliance 1
Medicinal Product
• As defined by EU laws:
Any substance or combination of substances presented as having properties for treating or preventing disease in human beings
• Must be approved/registered before allowing to be marketed
• Safety, efficacy and quality must be ensured
The role of the Regulatory Agencies to protect the health and safety of the population
2
Major groups of regulations
• Good Laboratory Practices (GLP)
• safety (preclinical studies)
• animal, tissue, and cell studies
• Good Manufacturing Practices (GMP)
• manufacturing and packaging
• Good Clinical Practices (GCP)
• safety and efficacy in human
• conduct of clinical trials 3
GLP Good Laboratory Practice (GLP) is a quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported
• Should apply to all non-clinical health and environmental safety studies required by regulations for the purpose of registering or licensing • pharmaceutical products
• pesticides
• food and feed additives
• cosmetic products
• veterinary drug products
• industrial chemicals
Non-clinical health and environmental safety studies covered by the Principles of Good Laboratory Practice include work conducted in the laboratory, in greenhouses, and in the field
4
GMP Good Manufacturing Practice is that part of Quality Management which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the Marketing Authorization, Clinical Trial Authorization or product specification. Good Manufacturing Practice is concerned with both production and quality control
• Applicable to the manufacture of
• manufacture of medicinal products for human use
• including medicinal gases, herbal medicinal products, radiopharmaceuticals, products derived from human blood or human plasma
• veterinary medicinal products
EU GMP Annex 13. Manufacture of Investigational Medicinal Products
5
GCP
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible
• GCP guideline should be followed when
• generating clinical trial data that are intended to be submitted to regulatory authorities
• other clinical investigations that may have an impact on the safety and well-being of human subjects
6
EU Legislation - Eudralex
• Basic Legislation • Volume 1 - EU pharmaceutical legislation for medicinal products for human use
• Volume 5 - EU pharmaceutical legislation for medicinal products for veterinary use
• Series of guidelines • Volume 2 - Notice to applicants and regulatory guidelines for medicinal
products for human use
• Volume 3 - Scientific guidelines for medicinal products for human use
• Volume 4 - Guidelines for good manufacturing practices for medicinal
products for human and veterinary use
• Volume 6 - Notice to applicants and regulatory guidelines for medicinal products for
veterinary use
• Volume 7 - Scientific guidelines for medicinal products for veterinary use
• Volume 8 - Maximum residue limits
• Volume 9 - Guidelines for pharmacovigilance for medicinal products for human and
veterinary use
• Volume 10 - Guidelines for clinical trial 7
GLP, GMP and GCP in the drug development
8
Common Focus across GXPs
• Organization and Personnel
• Facilities
• Equipment
• Materials
• Records and reports
• Ethical consideration
• Quality management
Data integrity, patient safety, quality oversight
9
10
Quality Management is a wide-ranging concept, which covers all matters, which individually or collectively influence the quality of a product
The size and complexity of the company’s activities should be taken into consideration when developing a new Pharmaceutical Quality System or modifying an existing one
Main elements of the quality system
11
Quality System – Quality Policy
12
Quality Policy
• Short document
• Demonstrates the management’s commitment
• Signed by the CEO and the Quality Director
Quality System - Organization
• Organization Chart
• Clearly defined reporting line
• Job descriptions
• Responsibilities
• Direct report
• Adequate authority to carry out responsibilities
• No gaps or overlaps in the responsibilities
13
Quality system - Resources
• Adequate number of personnel
• Necessary qualifications
• Practical experience
• Training
• professional training
• quality training
14
Quality System - Documentation
• Type of documents • Instruction (procedures, specifications etc.)
• Report /record
• Document life-cycle • Preparation
• Approval
• Distribution
• Withdrawal
• Archive 15
Quality Documents
16
Quality system - Processes
• All processes should be clearly defined, systematically reviewed
• Processes that affect quality • Risk analysis and risk management
• Management of non-compliances
• Corrective and preventive actions
• Management of deviations
• Management of change controls
• Management of quality complaints
• Release (GMP)
• Recall (GMP)
17
Quality system – Quality Goals
• Continuous improvement • Periodic review of the Quality System
• Results of audit and inspections
• Quality indicators
• Trend analysis
• Quality Program
18
Quality Organization
• Direct report to the management
• Must be independent
• Responsibilities • Implementing and maintaining quality
management system
• Management of quality documents
• Reviewing documents
• Performing audits
• Release (GMP)
• Quality training
• Advisory activities
19
Quality by Design ICH Q8 Pharmaceutical Development
20
Quality by Design ICH Q8 Pharmaceutical Development
• Aim of the Pharmaceutical Development
• design a quality product
• develop manufacturing process of the product
• consistently deliver the intended performance of the product
Quality must be built and cannot be tested into the products
Quality should be built in by design
21
Quality by Design
• Pharmaceutical Development • Defining the quality target product profile (QTPP)
• quality, safety and efficacy
• Identifying potential critical quality attributes (CQAs) • product characteristics must be kept within appropriate limits
to ensure the desired product quality
• Determining the critical quality attributes of drug substance and excipients
• Selecting an appropriate manufacturing process
• Defining a control strategy
• Systematic evaluation, understanding and refining of the formulation and manufacturing process
22
Design Space The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality
23
Design Space
Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post approval change process
Design space is proposed by the applicant and is subject to regulatory assessment and approval
24
25
QbD - Risk Management approach
Differing Approaches to Pharmaceutical Development
26
EMPIRICAL APPROACH SYSTEMATIC APPROACH (QBD)
Quality assured by testing and inspection
Quality built into product & process by design based on scientific understanding
Data intensive submission Knowledge rich submission – showing product knowledge and process understanding
Specifications based on batch history
Specifications based on product performance
Fixed manufacturing process Flexible process within design space
Focus on reproducibility Focus on robustness –understanding and controlling
Quality by Design
•More flexible regulatory approaches • Risk-based regulatory decisions (reviews and
inspections)
• Manufacturing process improvements, within the approved design space described in the dossier, without further regulatory review
• Reduction of post-approval submissions
• Real-time quality control, leading to a reduction of end-product release testing
27
Quality by Design in clinical development?
Quality System approach from the design to the end of the study
E.g.
• Study protocol should focus on proactive risk management
• scientific risk assessments
• operational risk assessments
• Selecting qualified investigators
• Ensure adequate monitoring (traditional, risk-based)
• Quality of the documentation
• Data quality
• Human factors concerns
• Risk mitigation
28
„Quality is never an accident.
It is always the result of intelligent
effort.” (John Ruskin)
29
THANK YOU FOR YOUR ATTENTION!
30
Recommended